<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04957472</url>
  </required_header>
  <id_info>
    <org_study_id>21-001-PRICO</org_study_id>
    <nct_id>NCT04957472</nct_id>
  </id_info>
  <brief_title>Multicenter Study of the Safety and Performance of Fabian-PRICO for Saturation Targeting Routine Use in the NICU</brief_title>
  <official_title>Multicenter Study of the Safety and Performance of Fabian-PRICO for Saturation Targeting Routine Use in the NICU</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vyaire Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vyaire Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is planned as a part of the post market clinical follow-up (PMCF) on a CE marked&#xD;
      product. The purpose of the study is to demonstrate, in a routine clinical environment across&#xD;
      a number of centers, that the fabian-PRICO can adequately maintain oxygen saturation, with&#xD;
      minimal staff intervention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized cross-over study. Subjects will be assigned to two, nominally 24-hour&#xD;
      interventions, one with standard manual titration of FiO2 and the other with automated&#xD;
      adjustment (PRICO). The order of these two interventions will be random.&#xD;
&#xD;
      In addition to the ventilators data, basic demographics (i.e., gestational age, birth weight,&#xD;
      age, weight at study) of the participating infants will be recorded in the eCRF.&#xD;
&#xD;
      This study has no additional follow-up visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Target Range Compliance:</measure>
    <time_frame>24 hours</time_frame>
    <description>Percent-Time with SpO2 a) &lt;80% and b) with &gt;98% SpO2 with FiO2&gt;21%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Avoidance of SpO2 Extremes:</measure>
    <time_frame>24 hours</time_frame>
    <description>Percent-Time with SpO2 a) &lt;80% and b) with &gt;98% SpO2 with FiO2&gt;21%</description>
  </secondary_outcome>
  <enrollment type="Anticipated">47</enrollment>
  <condition>Respiratory Insufficiency in Children</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>fabian HFO, fabian +nCPAP evolution and fabian Therapy evolution with PRICO function</intervention_name>
    <description>24 hours of automated control of FiO2</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Manual Control</intervention_name>
    <description>24 hours of manual control of FiO2</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Members of the Investigational team will periodically review records to identify and&#xD;
        maintain a pool of potential investigation candidates from the NICU. It is anticipated that&#xD;
        this pool will be significantly larger than capacity of the team to enroll into the&#xD;
        investigation.&#xD;
&#xD;
        The parents of potential candidates will be approached for discussion and consent prior to&#xD;
        the desired intervention.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Respiratory insufficiency of infants in the neonatal unit who require respiratory&#xD;
             support and supplemental oxygen in one of 4 the therapeutic categories (Intubated HFO,&#xD;
             Intubated CMV, Non-Invasive nasal mask, nasal cannula).&#xD;
&#xD;
          -  &lt;30 kg at study entry&#xD;
&#xD;
          -  Informed Consent Form obtained as per EC requirement&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not expected to complete 48 hours of the current respiratory support therapeutic&#xD;
             category&#xD;
&#xD;
          -  Congenital anomalies&#xD;
&#xD;
          -  Uncontrolled hemodynamics&#xD;
&#xD;
          -  Start of caffeine therapy within 12 hours&#xD;
&#xD;
          -  Attending physician does not believe participation of the patient is in their best&#xD;
             interest.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Wilińska, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre of Postgraduate Medical Education, SPSK im prof.W.Orłowskiego Warsaw</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Beata Łoniwska, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SPSK 2 Pomeranian Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Beata Rzepecka-Węglarz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Szpital Położniczo - Ginekologiczny Ujastek</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Pedro, MD</last_name>
    <phone>+1 (339) 293 9211</phone>
    <email>michael.pedro@vyaire.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andreas Waldmann</last_name>
    <email>andreas.waldmann@vyaire.com</email>
  </overall_contact_backup>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 30, 2021</study_first_submitted>
  <study_first_submitted_qc>June 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

